Randomized Phase Ii Study On The Influence Of Braf And Pik3ca Mutations On The Efficacy Of Folfiri Plus Bevacizumab (Bev) Or Cetuximab (Cet), As First Line Therapy Of Patients (Pts) With Ras Wild Type Metastatic Colorectal Carcinoma (Mcrc) And < 3 Baseline Circulating Tumor Cells (Bctcs).

JOURNAL OF CLINICAL ONCOLOGY(2019)

引用 1|浏览67
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要